The Technical Analyst
MERCK [MKKGY]
Exchange: OTC Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
MERCK Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.22% $32.74
America/New_York / 3 mai 2024 @ 15:51
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 70 866 mill |
| EPS: | 1.390 |
| P/E: | 23.55 |
| Earnings Date: | May 15, 2024 |
| SharesOutstanding: | 2 164.83 mill |
| Avg Daily Volume: | 0.108 mill |
| RATING 2024-05-03 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Buy | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.81x |
| Company: PE 23.55 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.75x |
| Company: PE 23.55 | industry: PE 31.46 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 32.18 - 33.30 ( +/- 1.71%) |
| ATR Model: 14 days |
Forecast:
16:00 - $32.74
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $32.74
Forecast 2: 16:00 - $32.74
Forecast 3: 16:00 - $32.74
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $32.74 (1.22% ) |
| Volume | 0.0320 mill |
| Avg. Vol. | 0.108 mill |
| % of Avg. Vol | 29.48 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MKKGY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MKKGY
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
Latest Press Releases
2021-09-12 18:05:00 - Press Release
Merck To Present Latest Highlights From Oncology Portfolio At Wclc And Esmo 2021
Darmstadt, germany--(business wire)--merck, a leading science and technology company, today announced research from company-sponsored, investigator-sponsored, and collaborative studies — including two oral and two mini-oral presentations — at this year's world conference on lung cancer, september 8-14, 2021, and the european society for medical oncology (esmo) congress, september 16-21, 2021. “analyses presented from ongoing and completed trials at both of these meetings have the potential to m
2021-08-17 21:02:00 - Press Release
Telix And Merck Kgaa, Darmstadt, Germany, To Commence Pan-cancer Clinical Combination Studies
Melbourne, australia, aug. 17, 2021 (globe newswire) -- telix pharmaceuticals limited (asx: tlx, ‘telix', the ‘company') today announces that it has entered into a pan-cancer clinical collaboration with merck kgaa, darmstadt, germany, to conduct combination studies with one of merck kgaa, darmstadt, germany's investigational proprietary dna damage response inhibitor (ddri) molecules in combination with each of telix's tlx591 (177lu-rosopatamab) and tlx250 (177lu-girentuximab) molecularly targeted radiation (mtr) therapeutic programs. this clinical collaboration builds on the success of a strategic research collaboration agreement between telix and merck kgaa, darmstadt, germany announced in august 2019...
2021-04-23 09:11:00 - Press Release
Merck Announces New Data Strengthening Evidence For Continued Safe And Effective Mavenclad® Use During The Covid-19 Pandemic
Darmstadt, germany--(business wire)--not intended for uk and u.s. based media merck, a leading science and technology company, today announced a new analysis from the magnify-ms sub-study showing a specific immune repopulation pattern in patients with relapsing multiple sclerosis (rms) treated with mavenclad® (cladribine tablets), which may contribute to their ability to fight infections and develop protective antibodies from vaccines. the data were presented at the 2021 american academy of neu
Latest News
2024-03-07 12:02:03 - Seeking Alpha
Merck KGaA (MKGAF) Q4 2023 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q4 2023 Results Conference Call March 7, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Garijo - Chair & CEO Helene von Roeder - CFO Matthias Heinzel - CEO, Life Science Sector Peter Guenter - CEO, Healthcare Business Kai Beckmann - CEO, Electronics Conference Call Participants Colin White - UBS Sophia Gray - JPMorgan Charlie Hayward - Bank of America Falko Friedrichs - Deutsche Bank Gary Steventon - BNP Paribas, Exane Edward Hall - Stifel Oliver Metzger - ODDO BHF Operator Dear ladies and gentlemen, welcome to the Merck Investor and Analyst Conference Call on the Fourth Quarter 2023. As a reminder, all participants will be in a listen-only mode.
2024-03-07 01:09:45 - Reuters
Merck KGaA forecasts return to organic earnings growth in 2024
Merck KGaA predicted a return to modest operating earnings growth, when adjusted for currency headwinds, citing a gradual recovery in demand for specialty materials that are used to make biotech drugs and semiconductors.
2023-12-06 11:25:01 - Proactive Investors
Merck KGaA's experimental MS drug fails in late stage trials sending shares tumbling
Merck KGaA shares plunged more than 12% on Wednesday after the company announced that its experimental multiple sclerosis (MS) drug evobrutinib failed to meet the primary endpoint in Phase 3 clinical trials. The company said that its drug did not reduce the annualized relapse rates in people with relapsing MS when compared to Sanofi's oral teriflunomide.
2023-12-05 15:53:45 - Reuters
Merck KGaA says MS drug fails in late-stage trials
Germany's Merck KGaA said on Tuesday the company's experimental multiple sclerosis drug evobrutinib did not meet the primary goal in highly anticipated late-stage trials.
2023-11-12 20:42:37 - Seeking Alpha
Evotec: Attractive Spec 'Buy', But Merck KGaA Is Still Better
Evotec SE's appeal is based on its valuation and upside potential in the drug discovery and development sector. The company's financial performance is average, with negative margins and subpar business model specifics for 2022. Despite some issues, EVO remains a leading player in the drug/pharma market with strong partnerships and revenue growth.
2023-11-09 01:03:47 - Reuters
Merck KGaA Q3 earnings down 20% on weak biotech, electronics demand
Germany's diversified group Merck KGaA reported a 20% decline in quarterly operating profit on weak demand for specialty materials that are used to make biotech drugs and semiconductors.
2023-10-30 04:45:45 - Reuters
Merck KGaA widens work on 'DNA damage' drugs in deal with China's Hengrui
Germany's Merck KGaA on Monday said it struck a collaboration deal with Chinese drugmaker Jiangsu Hengrui Pharmaceuticals to widen Merck's work in an area known as "DNA damage response" drugs.
2023-10-19 02:08:56 - Reuters
Merck KGaA says MS drug has blockbuster potential; key data expected in December
The CEO of Germany's Merck KGaA said the company's experimental multiple sclerosis drug can be a "blockbuster", an industry term for annual sales that exceed $1 billion, even after concerns emerged that it may cause liver damage.
2023-10-19 02:03:42 - Reuters
Merck KGaA raises prospect of return to sales growth next year
Germany's diversified group Merck KGaA has raised the prospect of returning to revenue growth next year, recovering from a slump in demand for its specialty materials to produce biotech drugs and semiconductors.
2023-09-20 09:13:54 - Proactive Investors
Exscientia stock surges on Merck KGaA partnership
Exscientia PLC shares climbed as much as 30% in pre-market trading on Wednesday after the precision-medicine company announced a new, multi-year collaboration with German science and technology company Merck KGaA, which could be worth hundreds of millions of dollars. The collaboration will involve using Exscientia's AI-driven precision drug design and discovery capabilities to discover novel small-molecule drug candidates across oncology, neuroinflammation and immunology, according to the company.